Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Bionor Pharma ASA : Notice of Extraordinary General Meeting 14 December 2016

Bionor Pharma ASA
Posted on: 23 Nov 16



Notice of Extraordinary General Meeting 14 December 2016

(Oslo, Norway, 23 November 2016) An Extraordinary General Meeting of Bionor Pharma ASA will be held on Wednesday 14 December 2016 at 16:30 hours CET (the "EGM") at KS Agenda Møtesenter, Haakon VIIs gate 9, Oslo, Norway.

On 21 November 2016 Bionor Pharma announced (the "Announcement") that the company has entered into an agreement to acquire the entire share capital of Solon Eiendom AS (the "Acquisition"). In connection the Company will do a Private Placement and a Subsequent Offering as further described in the Announcement. The Acquisition, the Private Placement and the Subsequent Offering are subject to shareholder approval and the Company accordingly call the EGM for the purpose of obtaining such shareholder approval. The largest shareholders of the Company, including Ferncliff Listed DAI, Lars H. Høie, Cipriano AS and Alden AS, have signed a lock-upundertaking until the EGM and have undertaken to vote in favour of such resolutions at the EGM.

The notice of the EGM is attached hereto and includes detailed registration and proxy instructions.

All relevant documents and link to online registration of attendance and advance voting can be found on .

Please note that to attend the EGM, attendants must be registered shareholders five working days prior to the meeting, i.e. 7 December 2016.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Further information
Einar J. Greve Chairman of the Board, Bionor Pharma ASA E-mail: Cell Phone: +47 900 27 766
Unni Hjelmaas Acting Chief Executive Officer, Bionor Pharma ASA E-mail: Cell Phone: +47 915 19 651
Cecilie Grue, Director Legal Affairs, Bionor Pharma ASA, E-mail: , Cell Phone: +47 991 62 486


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bionor Pharma ASA via GlobeNewswire

Last updated on: 24/11/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.